{
    "clinical_study": {
        "@rank": "16708", 
        "acronym": "NEXThaler", 
        "arm_group": [
            {
                "arm_group_label": "CHF 1535 NEXThaler 800/48 ug", 
                "arm_group_type": "Active Comparator", 
                "description": "single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate"
            }, 
            {
                "arm_group_label": "CHF 1535 NEXThaler PLACEBO", 
                "arm_group_type": "Placebo Comparator", 
                "description": "single dose administration of placebo via NEXThaler DPI"
            }, 
            {
                "arm_group_label": "CHF 1535 pMDI 200/12", 
                "arm_group_type": "Active Comparator", 
                "description": "single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate"
            }, 
            {
                "arm_group_label": "CHF 1535 100/6 pMDI 800/48", 
                "arm_group_type": "Active Comparator", 
                "description": "single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate"
            }, 
            {
                "arm_group_label": "CHF 1535 NEXThaler 200/12", 
                "arm_group_type": "Active Comparator", 
                "description": "single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate"
            }
        ], 
        "brief_summary": {
            "textblock": "The study aim is to compare the pharmacodynamic effects (cardiovascular effects- primary\n      variable: Heart rate over 4 hours post dosing- ) after administration of BDP and formoterol\n      administered as CHF 1535 100/6 NEXThaler DPI or CHF1535 pMDI at two different dose levels."
        }, 
        "brief_title": "A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of \"Nexthaler\" Dry Powder Inhaler in COPD Patients", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "The effects of both formulations on serum potassium and serum glucose and the general safety\n      and tolerability of study treatments will be also evaluated"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female adults (\u2265 40 and  \u2264 75 years old).\n\n          -  Outpatients with diagnosis of moderate/severe stable COPD, according to GOLD (Global\n             Initiative for Chronic Obstructive Lung Disease) guidelines update 2013 at least in\n             the 6 months before the screening visit.\n\n          -  A post-bronchodilator FEV1(Forced Expiratory Volume in one second) \u2265 40 and < 80% of\n             the predicted normal value and FEV1/FVC (Forced Vital Capacity) < 0.7, after 4 puffs\n             (4 x 100 \u00b5g) of salbutamol pMDI. If this criterion is not met at screening, the test\n             can be repeated once before commencing of the run-in period.\n\n          -  Ability to use pMDI (pressured metered-dose inhaler)and DPI (dry powder Inhaler)\n             devices\n\n          -  Current or past smoker of at least 10 pack/years where one pack-year is equivalent to\n             20 cigarettes per day for 1 year\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating female subjects.\n\n          -  Current diagnosis of Asthma (as defined by the current GINA (Global Initiative for\n             Asthma guidelines 2012 (update), or history of allergic rhinitis.\n\n          -  COPD exacerbations requiring systemic steroids and /or antibiotics and/or oral or\n             nebulized beta 2-agonists in the 4 weeks prior to screening and until randomization.\n\n          -  Lower Respiratory Tract Infection (LRTI) in the 4 weeks prior to screening and until\n             randomization.\n\n          -  Patients with serum potassium levels < 3.5 mEq/L (milliequivalent per liter).\n\n          -  History of substance abuse or drug abuse within 12 months prior to screening visit.\n\n          -  Known respiratory disorders other than COPD including but not limited to \u03b11\n             antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung\n             fibrosis, pulmonary hypertension, restrictive lung disease and interstitial lung\n             disease.\n\n          -  Intolerance or contra-indication to treatment with beta 2-agonists and/or inhaled\n             corticosteroids or allergy to any component of the study treatments.\n\n          -  Patients treated with non-cardioselective \u03b2-blockers in the month preceding the\n             screening visit or during the study period.\n\n          -  Patients who have clinically significant cardiovascular disease according to\n             investigator's judgement. Thus includes but is not limited to:\n\n               -  congestive heart failure (NYHA class > 3);\n\n               -  acute ischemic heart disease within the past 12 months of screening;\n\n               -  Sustained cardiac arrhythmias (supraventricular or ventricular,  >30 seconds\n                  duration) at or within 6 months of screening;\n\n               -  Non sustained cardiac arrhythmias (supraventricular or ventricular, > 3 beats <\n                  30 seconds and or ending spontaneously and or asymptomatic);\n\n               -  History of sustained and non-sustained cardiac arrhythmias (supraventricular or\n                  ventricular);\n\n               -  2nd or 3rd degree Atrioventricular conduction block;\n\n               -  Left Bundle Branch Block.\n\n          -  An abnormal 12-lead ECG (QRS> 120 msec, PR> 220 msec, HR < 40 bpm, Heart Rate > 110\n             bpm) at screening or at randomization.\n\n          -  Patients whose electrocardiogram (12-lead ECG) shows QTcF >450 ms for males or QTcF >\n             470 ms for females at screening or at randomisation.\n\n          -  Patients whose DBP/SBP is higher than: DBP 90 mmHg or SBP 160 mmHg at screening or at\n             randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000609", 
            "org_study_id": "CCD-01535BC1-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF 1535 NEXThaler 800/48 ug", 
                "intervention_name": "CHF 1535 NEXThaler 800/48", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHF 1535 NEXThaler 200/12", 
                "intervention_name": "CHF 1535 NEXThaler 200/12", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHF 1535 NEXThaler PLACEBO", 
                "intervention_name": "CHF 1535 NEXThaler PLACEBO", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHF 1535 pMDI 200/12", 
                "intervention_name": "CHF 1535 pMDI 200/12", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHF 1535 100/6 pMDI 800/48", 
                "intervention_name": "CHF1535 pMDI 800/48", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "pharmacodynamics COPD", 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M239Qz"
                }, 
                "name": "Medicine Evaluation Unit"
            }, 
            "investigator": {
                "last_name": "Dave Singh", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "5", 
        "official_title": "Phase II, Partial Blind, Randomized, Placebo Controlled, 5-way Cross-over Study to Evaluate the Pharmacodynamics of BDP(Beclomethasone Diproprionate)/B17MP (Beclomethasone-17-Monoproprionate) and FORMOTEROL FUMARATE (FF) Across Two Different Dose Levels of CHF 1535 NEXThaler DPI (Dry Powder Inhaler) and CHF 1535 pMDI (Pressurized Metered-dose Inhaler)in Adult COPD (Chronic Obstructive Pumonary Disease) Patients", 
        "overall_contact": {
            "email": "enquiries@meu.org.uk", 
            "last_name": "Prof.Dave Singh, 1", 
            "phone": "01619464050"
        }, 
        "overall_official": {
            "affiliation": "Medicine Evaluation Unit, Manchester (UK)", 
            "last_name": "Dave Singh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Average 4-hour Heart Rate bpm (beats per minutes)", 
            "safety_issue": "Yes", 
            "time_frame": "4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "QTcF (QT interval Fridericia's formula corrected) (milliseconds), QRS (milliseconds) and PR (milliseconds) intervals, PAC (Premature Atrial Contraction- percentage) burden, PVC (Premature Ventricular Contraction-percentage) burden, Blood Pressure (mmHg)", 
            "safety_issue": "Yes", 
            "time_frame": "-45, -30, -15min pre-dose, 5, 10, 20, 30, 45min, 1, 1.5, 2, 3, 4, 5, 5, 7, 8, 10 12 hr post dose"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}